Ultragenyx Pharmaceutical Inc. (RARE) research: valuation against peers, fundamentals over time, risk and news coverage
ChartVs peersValuationValue mapQuartersScaleMarginsTrajectoryCash qualityPer shareReinvestmentBalance sheetStreetRiskSeasonalityOur coverage
RARE
Ultragenyx Pharmaceutical Inc.USD
26.53
+2.79% today
Market cap
—
P/E trailing
—
P/E forward
—
EV/EBITDA
—
Op margin
—
Rev growth
—
Div yield
—
Beta
—
Price navigator — RARE
No data in this window.
INDY NEWS coverage of RARE1
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- BREAKING STORYBEARISHBiotech Downgrades Hit Ultragenyx on Trial Failure, Moderna on Valuation
Two separate analyst downgrades hit biotech stocks, with Ultragenyx cut on a clinical trial failure and Moderna cut on valuation grounds.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.